Zealand Pharma and Helsinn Healthcare SA Announce Helsinn’s Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea
5/28/2013 9:09:30 AM
More...
|
Zealand Pharma Receives Milestone Payment from Helsinn Healthcare SA
12/9/2010 11:24:11 AM
More...
|
Helsinn Healthcare SA and Eisai Inc. (ESALF.PK) Extend Relationship
6/9/2010 9:35:36 AM
More...
|
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc.
1/28/2009 11:27:12 AM
More...
|
Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma
12/11/2008 8:52:29 AM
More...
|
Zealand Pharma and Helsinn Healthcare SA Sign a €140 Million (US$176.8 Million) Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
12/1/2008 11:21:36 AM
More...
|
MGI PHARMA, INC. (MOGN) and Helsinn Healthcare SA Announce sNDA for Aloxi Capsules Accepted for Review by U.S FDA
1/3/2008 10:42:39 AM
More...
|
MGI PHARMA, INC. (MOGN) and Helsinn Healthcare SA Announce Submission of Supplemental New Drug Application for Aloxi(R) Capsules
10/30/2007 12:24:33 PM
More...
|
MGI PHARMA, INC. (MOGN) and Helsinn Healthcare SA Announce Aloxi(R) sNDA Approval Allowing for Repeated Dosing for Cancer Patients Receiving Multiple Day Chemotherapy Regimens
9/4/2007 11:49:13 AM
More...
|
MGI PHARMA, INC. (MOGN) and Helsinn Healthcare SA Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA
7/9/2007 12:00:44 PM
More...
|
|